• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Skin biopsy can help identify patients with Parkinson’s disease

Bioengineer by Bioengineer
March 15, 2022
in Biology
Reading Time: 3 mins read
0
Confocal microscope study of p-syn deposits in a dermal arteriole of a patient with PD
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Amsterdam, March 15, 2022 – The diagnosis of Parkinson’s disease (PD) is currently based on consensus clinical criteria. A novel study reported in the Journal of Parkinson’s Disease has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein (p-syn) in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau. This development may help the early identification and differential diagnosis of PD among the various parkinsonism subtypes.

Confocal microscope study of p-syn deposits in a dermal arteriole of a patient with PD

Credit: Dr. Alex Incensi

Amsterdam, March 15, 2022 – The diagnosis of Parkinson’s disease (PD) is currently based on consensus clinical criteria. A novel study reported in the Journal of Parkinson’s Disease has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein (p-syn) in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau. This development may help the early identification and differential diagnosis of PD among the various parkinsonism subtypes.

The main parkinsonian symptoms are shared with other synucleinopathies, as well as with atypical parkinsonism, including progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), both of which are due to the accumulation of another protein, tau. Despite the clinical overlap with PD, PSP is characterized by 4-repeat tau deposits, mainly in the basal ganglia, brainstem, and cerebellum, and CBS is a clinical syndrome with a heterogeneous underlying neuropathology, represented mainly by tauopathies but also by synucleinopathies.

“Research in PD and other neurodegenerative disorders is to find treatments able to halt and ideally prevent the accumulation the pathological proteins responsible for the different disorders. Our lab, led by Prof. Rocco Liguori and Dr. Vincenzo Donadio, has spent the last decade looking for reliable biomarkers of PD and related disorders to achieve an accurate and early diagnosis,” explained corresponding author Maria Pia Giannoccaro, PhD, Department of Biomedical and Neuromotor Sciences, University of Bologna and IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

“This research sprang from the same effort. Our aim was to see if we could distinguish PD from two potential mimics, PSP and CBS, and to explore the potential for using this approach to support clinical diagnosis,” Dr. Giannoccaro continued.

Investigators recruited 26 patients with PD, 26 patients with either PSP (18) or CBS (8), and 26 healthy individuals from May 2014 to April 2017. All individuals underwent skin biopsy in three sites, the leg, the thigh, and the cervical area, to study p-syn deposits in skin nerves. They found that all except two of the PSP/CBS patients had no skin p-syn deposits, as well as all the healthy individuals. Conversely, all PD patients showed p-syn deposition.

The investigators were surprised by the finding that two patients diagnosed with PSP and CBS, respectively, had p-syn skin deposits. One possibility is that these two patients were misdiagnosed, however, the diagnosis was confirmed by clinical and MRI findings. Another intriguing possibility is that some patients have a mixed pathology with multiple neurodegenerative disorders occurring at the same time. Both patients had some atypical features more typical of PD that could suggest an atypical synucleinopathy presentation.

“To our knowledge this is the largest study comparing in vivo the peripheral deposition of misfolded alpha-synuclein in PD and PSP/CBS cases,” commented Dr. Giannoccaro. “We showed that the presence of skin p-syn deposits accurately distinguishes patients with PD from those with atypical parkinsonism. Early differentiation and accurate in vivo diagnosis are important for adequate clinical management and patient care since the treatment and prognosis of PD, PSP and CBS are different.

The investigators recommend further studies including larger samples of patients to confirm these results. Moreover, in the near future, it could be relevant for the recruitment of patients in clinical trials of potential disease-modifying therapies.

PD is a slowly progressive disorder that affects movement, muscle control, and balance. It is the second most common age-related neurodegenerative disorder affecting about 3% of the population by the age of 65 and up to 5% of individuals over 85 years of age.



DOI

10.3233/JPD-212904

Method of Research

Experimental study

Subject of Research

People

Article Title

Presence of Skin α -Synuclein Deposits Discriminates Parkinson’s Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome

Article Publication Date

15-Feb-2022

Share12Tweet8Share2ShareShareShare2

Related Posts

Conserved Small Sequences Revealed by Yeast Ribo-seq

Conserved Small Sequences Revealed by Yeast Ribo-seq

October 3, 2025
Atlas Reveals Testicular Aging Across Species

Atlas Reveals Testicular Aging Across Species

October 2, 2025

Stem Cell Reports Announces New Additions to Its Editorial Board

October 2, 2025

New Insights on Bluetongue Virus in South Asia

October 2, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    92 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    85 shares
    Share 34 Tweet 21
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Global Insights on Sustaining Practice-Based Research Networks

Scientists Harness Ultrasound Holograms to Modulate Brain Networks

Sleep Patterns in U.S. Kids with Neurodiversity

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.